This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2024 Sep;13(9):2103.

doi: 10.1007/s40121-024-01030-0.

Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor

Takayuki Katsube¹, Safwan Kezbor², Ryosuke Shimizu³, Ryuji Kubota³

Affiliations

Affiliations

¹ Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-Ku, Osaka, 541-0042, Japan. takayuki.katsube@shionogi.co.jp.
² Shionogi Inc., 400 Campus Drive, 4th Fl., Florham Park, NJ, 07932, USA.
³ Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-Ku, Osaka, 541-0042, Japan.

PMID: 39136875
PMCID: PMC11343925
DOI: 10.1007/s40121-024-01030-0

Published Erratum

Correction to: Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS‑CoV‑2 3CL Protease Inhibitor

Takayuki Katsube et al. Infect Dis Ther. 2024 Sep.

. 2024 Sep;13(9):2103.

doi: 10.1007/s40121-024-01030-0.

Authors

Takayuki Katsube¹, Safwan Kezbor², Ryosuke Shimizu³, Ryuji Kubota³

Affiliations

¹ Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-Ku, Osaka, 541-0042, Japan. takayuki.katsube@shionogi.co.jp.
² Shionogi Inc., 400 Campus Drive, 4th Fl., Florham Park, NJ, 07932, USA.
³ Clinical Pharmacology and Pharmacokinetics, Shionogi & Co., Ltd., 3-13, Imabashi 3-Chome, Chuo-Ku, Osaka, 541-0042, Japan.

PMID: 39136875
PMCID: PMC11343925
DOI: 10.1007/s40121-024-01030-0

No abstract available

PubMed Disclaimer

Erratum for

Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor.
Katsube T, Kezbor S, Shimizu R, Kubota R. Katsube T, et al. Infect Dis Ther. 2024 Mar;13(3):597-607. doi: 10.1007/s40121-024-00946-x. Epub 2024 Mar 9. Infect Dis Ther. 2024. PMID: 38460082 Free PMC article.

Similar articles

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Shimizu R, et al. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0063222. doi: 10.1128/aac.00632-22. Epub 2022 Sep 12. Antimicrob Agents Chemother. 2022. PMID: 36094202 Free PMC article. Clinical Trial.
Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S, Matsui Y, Adachi T, Morikawa Y, Inoue K, Takebayashi S, Nobori H, Rokushima M, Tachibana Y, Kato T. Kawashima S, et al. Biochem Biophys Res Commun. 2023 Feb 19;645:132-136. doi: 10.1016/j.bbrc.2023.01.040. Epub 2023 Jan 14. Biochem Biophys Res Commun. 2023. PMID: 36689809 Free PMC article.
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
Ip JD, Wing-Ho Chu A, Chan WM, Cheuk-Ying Leung R, Umer Abdullah SM, Sun Y, Kai-Wang To K. Ip JD, et al. EBioMedicine. 2023 May;91:104559. doi: 10.1016/j.ebiom.2023.104559. Epub 2023 Apr 14. EBioMedicine. 2023. PMID: 37060743 Free PMC article.
[Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA^® Tablets 125 ‍mg)].
Tsuge Y, Ariwa Y, Shibata K. Tsuge Y, et al. Nihon Yakurigaku Zasshi. 2024;159(4):264-281. doi: 10.1254/fpj.24017. Nihon Yakurigaku Zasshi. 2024. PMID: 38945910 Review. Japanese.
Ensitrelvir Fumaric Acid: First Approval.
Syed YY. Syed YY. Drugs. 2024 Jun;84(6):721-728. doi: 10.1007/s40265-024-02039-y. Epub 2024 May 25. Drugs. 2024. PMID: 38795314 Review.

See all similar articles

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Miscellaneous
- NCI CPTAC Assay Portal